Inovio Pharmaceuticals (INO) saw its loss widen to $23.09 million, or $0.31 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $8.04 million, or $0.11 a share. Revenue during the quarter grew 27.94 percent to $10.38 million from $8.11 million in the previous year period.
Operating loss for the quarter was $21.93 million, compared with an operating loss of $15.45 million in the previous year period.
Working capital drops significantlyInovio Pharmaceuticals has witnessed a decline in the working capital over the last year. It stood at $66.78 million as at Mar. 31, 2017, down 47.50 percent or $60.43 million from $127.20 million on Mar. 31, 2016. Current ratio was at 2.67 as on Mar. 31, 2017, down from 4.81 on Mar. 31, 2016. Days sales outstanding went down to 80 days for the quarter compared with 104 days for the same period last year.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]